A Double-Blind, Randomized, Placebo-Controlled, Age Descending and Expansion Phase 2 Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 Years.

Trial Profile

A Double-Blind, Randomized, Placebo-Controlled, Age Descending and Expansion Phase 2 Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 Years.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 09 Jul 2017

At a glance

  • Drugs TAK 003 (Primary) ; TAK 003 (Primary)
  • Indications Dengue
  • Focus Adverse reactions
  • Sponsors Takeda
  • Most Recent Events

    • 07 Sep 2016 According to a media release, interim results of this trial were presented at the American Society of Tropical Medicine and Hygiene (ASTMH) meeting in October 2015.
    • 19 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 15 Sep 2015 Results from phase Ib study published in the Vaccine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top